Glen  Burkhardt net worth and biography

Glen Burkhardt Biography and Net Worth

Glen is an HR executive with more than 25 years of experience in the life sciences industry. Most recently he served as Vice President of Human Resources for Hologic, Inc., prior to which he was Senior Director of Human Resources at Onyx Pharmaceuticals from 2011 until its sale to Amgen in 2014. Earlier in his career, Glen held several HR roles at Eli Lilly and Company, including leadership of their global talent management function. Glen received BS and BArch degrees from Ball State University and an MBA from the Indiana University Kelley School of Business.

What is Glen Burkhardt's net worth?

The estimated net worth of Glen Burkhardt is at least $0.00 as of May 20th, 2021. Mr. Burkhardt owns 3,811 shares of PhaseBio Pharmaceuticals stock worth more than $0 as of April 19th. This net worth estimate does not reflect any other investments that Mr. Burkhardt may own. Learn More about Glen Burkhardt's net worth.

How do I contact Glen Burkhardt?

The corporate mailing address for Mr. Burkhardt and other PhaseBio Pharmaceuticals executives is 1 Great Valley Parkway Suite 30, Malvern PA, 19355. PhaseBio Pharmaceuticals can also be reached via phone at (610) 981-6500 and via email at [email protected]. Learn More on Glen Burkhardt's contact information.

Has Glen Burkhardt been buying or selling shares of PhaseBio Pharmaceuticals?

Glen Burkhardt has not been actively trading shares of PhaseBio Pharmaceuticals during the last ninety days. Most recently, Glen Burkhardt sold 11,248 shares of the business's stock in a transaction on Monday, May 23rd. The shares were sold at an average price of $0.79, for a transaction totalling $8,885.92. Learn More on Glen Burkhardt's trading history.

Who are PhaseBio Pharmaceuticals' active insiders?

PhaseBio Pharmaceuticals' insider roster includes Glen Burkhardt (VP), and Clay Thorp (Director). Learn More on PhaseBio Pharmaceuticals' active insiders.

Glen Burkhardt Insider Trading History at PhaseBio Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/23/2022Sell11,248$0.79$8,885.92View SEC Filing Icon  
11/19/2021Sell5,766$2.37$13,665.42View SEC Filing Icon  
5/20/2021Sell3,811$3.29$12,538.193,811View SEC Filing Icon  
11/23/2020Sell3,497$3.45$12,064.653,497View SEC Filing Icon  
See Full Table

Glen Burkhardt Buying and Selling Activity at PhaseBio Pharmaceuticals

This chart shows Glen Burkhardt's buying and selling at PhaseBio Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

PhaseBio Pharmaceuticals Company Overview

PhaseBio Pharmaceuticals logo
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.
Read More

Today's Range

Now: N/A

50 Day Range

MA: N/A

2 Week Range

Now: N/A

Volume

N/A

Average Volume

848,888 shs

Market Capitalization

$3.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.57